Hypoxic fetoplacental vasoconstriction in humans is mediated by potassium channel inhibition

1 Department of Physiology, Charles University Second Medical School, 15000 Prague 5; 2 Centre for Experimental Cardiovascular Research, 14220 Prague 4; 3 Institute for the Care of Mother and Child, 14300 Prague 4-Podolí, Czech Republic; 4 Vascular Biology Group, Cardiology Division, University of Alberta School of Medicine, Edmonton; and 5 Physiology Department, University of Alberta, Edmonton, Alberta T6G 2B7, Canada Fetal to maternal blood flow matching in the placenta, necessary for optimal fetal blood oxygenation, may occur via hypoxic fetoplacental vasoconstriction (HFPV). We hypothesized that HFPV is mediated by K + channel inhibition in fetoplacental vascular smooth muscle, as occurs in several other O 2 -sensitive tissues. With the use of an isolated human placental cotyledon perfused at a constant flow rate, we found that hypoxia reversibly increased perfusion pressure by >20%. HFPV was unaffected by cyclooxygenase or nitric oxide synthase inhibition. HFPV and 4-aminopyridine, an inhibitor of voltage-dependent K + (K v ) channels, increased pressure in a nonadditive manner, suggesting they act via a common mechanism. Iberiotoxin, a large conductance Ca 2+ -sensitive K + (BK Ca ) channel inhibitor, had little effect on normoxic pressure. Immunoblotting and RT-PCR showed expression of several putative O 2 -sensitive K + channels in peripheral fetoplacental vessels. In patch-clamp experiments with smooth muscle cells isolated from peripheral fetoplacental arteries, hypoxia reversibly inhibited K v but not BK Ca or ATP-dependent currents. We conclude that human fetoplacental vessels constrict in response to hypoxia. This response is largely mediated by hypoxic inhibition of K v channels in the smooth muscle of small fetoplacental arteries. fetal growth retardation; Kv1.5 channel; O 2 sensing